Lixte Biotech Hlds (LIXT) Stock Price, Quote & News

Company Profile

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab t...

Industry: Biotechnology

Sector: Healthcare

Phone: 631 830 7092

Fax: 631 982 5050

Website: lixte.com

Address:

680 East Colorado Boulevard, Suite 180, Pasadena, United States

WallStreetVice May. 11 at 2:58 PM

$FATE $ODYS $LIXT $AVTX 71::

0 · Reply

DonutHole May. 8 at 5:09 PM

$LIXT added to the list. https://www.realcreativeagency.com/best-penny-stocks-to-watch/#LIXT

0 · Reply

OfficialStocktwitsUser May. 8 at 2:42 AM

$LIXT RSI: 69.41, MACD: 0.3227 Vol: 0.53, MA20: 3.61, MA50: 3.18 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday May. 6 at 4:35 AM

$LIXT

0 · Reply

RETAlerts May. 5 at 8:09 PM

Scanner caught the setup on $LIXT early. Clean consolidation before the move. +9.2% now shows why algo systems flag this pattern.

0 · Reply

topstockalerts May. 5 at 8:08 PM

$LIXT this just keeps pushing without much effort

0 · Reply

KoalaFlipper May. 5 at 4:05 PM

$LIXT check out $OTLK

0 · Reply

ReadyMate May. 5 at 3:48 PM

$LIXT anyone here? Any idea what just happened?

1 · Reply

NetworkNewsWire Apr. 24 at 7:07 PM

TinyGemsBreaks – $LIXT Unlocking New Potential in Precision Cancer Treatment https://ibn.fm/ro6jj

0 · Reply

Love_To_Learn Apr. 22 at 1:11 PM

$LIXT making a change to u

1 · Reply

Lixte Biotechnology presents preliminary LB100 results

Apr 13, 2026, 8:00 AM EDT - 4 weeks ago

Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

Mar 31, 2026, 3:45 PM EDT - 6 weeks ago

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

2026-02-18T13:20:27.000Z - 3 months ago

Lixte Biotechnology appoints Sidney Braun as CEO, Liora

Feb 18, 2026, 8:00 AM EST - 3 months ago

LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

Jan 21, 2026, 8:00 AM EST - 4 months ago

DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

Jan 20, 2026, 8:00 AM EST - 4 months ago

LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

2026-01-13T13:42:44.000Z - 4 months ago

Lixte Biotechnology engages IBN for corporate communications

2025-12-23T13:20:27.000Z - 5 months ago

Lixte Biotechnology expands collaboration to expand trial with LB-100

Dec 23, 2025, 8:00 AM EST - 5 months ago

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

2025-12-18T14:05:36.000Z - 5 months ago

Lixte Biotechnology prices 1.05 units at $4.09 in registered direct offering

Dec 8, 2025, 8:30 AM EST - 5 months ago

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities

Dec 3, 2025, 11:00 AM EST - 5 months ago

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

Dec 3, 2025, 8:00 AM EST - 5 months ago

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

2025-11-25T13:45:50.000Z - 6 months ago

Lixte Biotechnology acquires Liora’s proton therapy platform

Nov 25, 2025, 8:30 AM EST - 6 months ago

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

Oct 29, 2025, 8:00 AM EDT - 7 months ago

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

2025-10-16T12:11:44.000Z - 7 months ago

Lixte Biotechnology outlines its Q4 priorities, provides development updates

Oct 16, 2025, 8:00 AM EDT - 7 months ago

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Sep 16, 2025, 8:30 AM EDT - 8 months ago

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

Sep 15, 2025, 5:40 PM EDT - 8 months ago

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

2025-09-10T20:35:40.000Z - 8 months ago

Lixte Biotechnology purchases 10.5 Bitcoin, 300 Ethereum for $2.6M

Sep 10, 2025, 4:05 PM EDT - 8 months ago

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

Sep 5, 2025, 8:35 AM EDT - 8 months ago

24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor

2025-09-03T12:21:32.000Z - 9 months ago

Lixte Biotechnology appoints two new board members, Stazzone as CFO

Sep 3, 2025, 8:00 AM EDT - 9 months ago

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

Aug 27, 2025, 8:15 AM EDT - 9 months ago

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

Aug 25, 2025, 8:05 AM EDT - 9 months ago

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

Aug 19, 2025, 11:18 AM EDT - 9 months ago

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

2025-08-18T12:16:08.000Z - 9 months ago

Lixte Biotechnology provides update on recent corporate activities

Aug 18, 2025, 8:00 AM EDT - 9 months ago

LIXTE Biotechnology Holdings Provides Corporate Update

Aug 14, 2025, 9:06 PM EDT - 9 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Aug 14, 2025, 8:05 AM EDT - 9 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

Aug 13, 2025, 8:49 AM EDT - 9 months ago

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

2025-08-13T11:45:10.000Z - 9 months ago

Lixte Biotechnology updates treasury policy to include cryptocurrency

Aug 13, 2025, 7:30 AM EDT - 9 months ago

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

2025-07-16T12:10:21.000Z - 10 months ago

Lixte regains compliance with Nasdaq’s Continued Listing requirements

Jul 16, 2025, 8:05 AM EDT - 10 months ago

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Jul 9, 2025, 5:15 PM EDT - 11 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

2025-07-09T12:26:48.000Z - 11 months ago

Lixte Biotechnology announces publication in Nature journal on LB100 trials

Jul 9, 2025, 8:05 AM EDT - 11 months ago

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Jul 8, 2025, 2:57 PM EDT - 11 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Jul 2, 2025, 4:05 PM EDT - 11 months ago

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Jul 1, 2025, 4:15 PM EDT - 11 months ago

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

2025-04-04T20:10:25.000Z - 1 year ago

Lixte Biotechnology files to sell 467,393 shares of common stock for holders

2025-03-31T12:40:08.000Z - 1 year ago

Lixte Biotechnology launches new study in collaboration with NKI on LB-100

Mar 31, 2025, 8:30 AM EDT - 1 year ago

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

2025-03-27T12:47:18.000Z - 1 year ago

Lixte Biotechnology provides update on progress with LB-100

Mar 27, 2025, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

2025-03-10T12:40:43.000Z - 1 year ago

Lixte announces online publication of new pre-clinical data in BioXriv

2025-02-25T13:56:36.000Z - 1 year ago

Lixte Biotechnology adds Lurie Cancer Center as second site in LB-100 trial

Feb 25, 2025, 8:30 AM EST - 1 year ago

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

2025-02-13T15:43:44.000Z - 1 year ago

Lixte Biotechnology announces closing of $1.05M registered direct offering

Feb 13, 2025, 10:35 AM EST - 1 year ago

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 11, 2025, 8:42 AM EST - 1 year ago

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 10, 2025, 5:00 PM EST - 1 year ago

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

Sep 4, 2024, 8:30 AM EDT - 1 year ago

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Aug 26, 2024, 8:30 AM EDT - 1 year ago

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Aug 19, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Provides Update On Recent Activities and Developments

Aug 15, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Aug 14, 2024, 10:50 PM EDT - 1 year ago

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Jun 14, 2024, 11:00 AM EDT - 2 years ago

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Jun 14, 2024, 9:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Jun 6, 2024, 8:30 AM EDT - 2 years ago

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Jun 3, 2024, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

May 20, 2024, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings Provides Update on Recent Activities

May 8, 2024, 9:25 AM EDT - 2 years ago

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

Mar 21, 2024, 8:30 AM EDT - 2 years ago

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Feb 27, 2024, 8:30 AM EST - 2 years ago

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

WallStreetVice May. 11 at 2:58 PM

$FATE $ODYS $LIXT $AVTX 71::

0 · Reply

DonutHole May. 8 at 5:09 PM

$LIXT added to the list. https://www.realcreativeagency.com/best-penny-stocks-to-watch/#LIXT

0 · Reply

OfficialStocktwitsUser May. 8 at 2:42 AM

0 · Reply

SuperGreenToday May. 6 at 4:35 AM

$LIXT

0 · Reply

RETAlerts May. 5 at 8:09 PM

Scanner caught the setup on $LIXT early. Clean consolidation before the move. +9.2% now shows why algo systems flag this pattern.

0 · Reply

topstockalerts May. 5 at 8:08 PM

$LIXT this just keeps pushing without much effort

0 · Reply

KoalaFlipper May. 5 at 4:05 PM

$LIXT check out $OTLK

0 · Reply

ReadyMate May. 5 at 3:48 PM

$LIXT anyone here? Any idea what just happened?

1 · Reply

NetworkNewsWire Apr. 24 at 7:07 PM

TinyGemsBreaks – $LIXT Unlocking New Potential in Precision Cancer Treatment https://ibn.fm/ro6jj

0 · Reply

Love_To_Learn Apr. 22 at 1:11 PM

$LIXT making a change to u

1 · Reply

Investor6 Apr. 21 at 6:47 AM

$PMAX June 2025, Pursglove became CEO of Lixte ( $LIXT ) . LIXT went from $1.10 to $5.40 in three months.

0 · Reply

NetworkNewsWire Apr. 17 at 5:52 PM

MissionIRNewsBreaks – $LIXT Positions LB-100 as Novel Approach in Cancer Treatment Landscape https://ibn.fm/yoogt

0 · Reply

NetworkNewsWire Apr. 17 at 5:38 PM

MissionIRNewsBreaks – $LIXT Positions LB-100 as Novel Approach in Cancer Treatment Landscape https://ibn.fm/yoogt

0 · Reply

NetworkNewsWire Apr. 15 at 4:51 PM

Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients $LIXT https://ibn.fm/WNIG7

0 · Reply

focafoca99 Apr. 13 at 3:39 PM

$LIXT reported encouraging interim ovarian-cancer data for LB-100 plus dostarlimab and has already started enrolling an expanded higher-exposure cohort.

0 · Reply

NetworkNewsWire Apr. 13 at 3:31 PM

BioMedNewsBreaks — $LIXT Reports Interim Ovarian Cancer Trial Results at SGO Conference https://ibn.fm/alcex

0 · Reply

NetworkNewsWire Apr. 10 at 6:13 PM

$LIXT Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion https://ibn.fm/Glko3

0 · Reply

NetworkNewsWire Apr. 9 at 5:24 PM

$LIXT Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships https://ibn.fm/kAXl6

0 · Reply

Disrupter Apr. 1 at 3:56 PM

$LIXT sleeping beast 🐗

0 · Reply

NetworkNewsWire Apr. 1 at 2:48 PM

MissionIRNewsBreaks – $LIXT Files 2025 Form 10-K, Highlights Transformational Year https://ibn.fm/RjlAM

0 · Reply

NetworkNewsWire Mar. 31 at 7:53 PM

$LIXT Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes https://ibn.fm/lTWU0

0 · Reply

NetworkNewsWire Mar. 30 at 7:48 PM

$LIXT Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials https://ibn.fm/QpnEw

0 · Reply

Market Cap	59.83M
Revenue (ttm)	0.00
Net Income (ttm)	-6.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	40,899
Avg Vol	47,536
Day's Range	N/A - N/A
Shares Out	11.62M
Stochastic %K	79%
Beta	1.04
Analysts	Strong Buy
Price Target	N/A